A Clinical Trial of Three Medicines (Elranatamab Plus Carfilzomib and Dexamethasone) in People With Relapsed Refractory Multiple Myeloma

• Status: Recruiting
• Trial end date: 2026-10-14

Summary

The purpose of this study is to understand the effects of elranatamab plus carfilzomib and dexamethasone for the treatment of people with multiple myeloma. Multiple myeloma is a form of cancer in the bone that forces healthy blood cells out. The investigators are seeking people who:

• Are male and female with multiple myeloma.

• Have received at least 1 but no more than 3 lines of therapy for multiple myeloma.

• Are 18 years of age or older.

• A female participant is eligible if she is not pregnant or breastfeeding. She is required to use birth control throughout the study.

All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants will receive the first dose of carfilzomib to see if it is safe. Afterwards, they will receive weekly carfilzomib as an IV infusion (given directly into a vein). Participants will also receive weekly dexamethasone either by mouth (as a pill) or by IV infusion.

The investigators will examine the experiences of people receiving the study medicines. This will help participants determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.

• Phase: Phase 1

Details

• Lead Sponsor: Pfizer